Gilead Sciences is set to present over 40 research abstracts at The Liver Meeting® 2024, highlighting its commitment to advancing liver disease research. A significant portion of these presentations will focus on new data for primary biliary cholangitis (PBC), including findings from the RESPONSE trial showcasing the efficacy and safety of Livdelzi® (seladelpar) in patients with PBC and compensated cirrhosis. Additional data will delve into Livdelzi’s impact on pruritus, a common and often debilitating symptom of PBC, and long-term efficacy and safety results from the ongoing ASSURE study.
Beyond PBC, Gilead will share an interim analysis of the Phase 3 MYR301 study, evaluating bulevirtide monotherapy in individuals with hepatitis Delta virus (HDV). This analysis will assess if patients maintain positive virological and biochemical responses one year after discontinuing bulevirtide treatment. Furthermore, Gilead will present 144-week data on patient-reported outcomes for those receiving the 2 mg dose of bulevirtide, adding to the growing body of long-term data for this HDV treatment.
Additional research to be presented includes safety and tolerability outcomes for Epclusa® (velpatasvir/sofosbuvir) in pregnant individuals with chronic HCV, real-world findings from the SVR10K study demonstrating the effectiveness of direct-acting antivirals against all HCV genotypes, and late-breaking data from a Phase 2a study assessing novel combination therapies for chronic hepatitis B virus (HBV). Gilead’s presence at the conference underscores its commitment to addressing unmet needs and improving treatment outcomes for individuals living with various liver diseases.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.